先瑞达医疗-B(06669.HK) 公布,收到中国国家药品监督管理局对RT-Zero的注册批准。公司将适时开展营销活动。RT-Zero为一种高压PTCA球囊,设计用于冠状动脉缺血患者冠脉狭窄部分及慢性全闭塞病变的球囊扩张,以改善心肌灌注。(de/d)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.